Imfinzi (durvalumab)

Imfinzi (Durvalumab) is a human monoclonal antibody immunotherapy that belongs to a class of medicines known as programmed death-ligand 1 (PD-L1) inhibitors. It is designed to enhance the body’s natural immune response against cancer by blocking the interaction between PD-L1 on tumor cells and PD-1 receptors on immune cells. This action helps restore immune system activity, enabling it to identify and destroy cancer cells more effectively.

Imfinzi is approved for the treatment of various cancers, including unresectable stage III non-small cell lung cancer (NSCLC) following chemoradiotherapy, extensive-stage small cell lung cancer (ES-SCLC), biliary tract cancer, and certain other advanced malignancies in specific treatment settings. Depending on the indication, it may be administered as a single-agent therapy or in combination with chemotherapy and other anticancer treatments.

Administered intravenously under the supervision of qualified healthcare professionals, Imfinzi has demonstrated significant clinical benefits, including improved overall survival, prolonged progression-free survival, and durable treatment responses in eligible patients. Its ability to activate the immune system against cancer has made it an important component of modern immuno-oncology treatment strategies.

As a leading PD-L1 inhibitor, Imfinzi represents a major advancement in cancer care by offering a precision-based immunotherapy approach that helps improve patient outcomes across multiple cancer types. Its proven efficacy and expanding clinical applications continue to strengthen its role in the evolving landscape of oncology treatment.